- Home
- SKYE vs BDTX Comparison
SKYE vs BDTX Comparison
Compare SKYE & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- BDTX
- Stock Information
- Founded
- SKYE 2012
- BDTX 2014
- Country
- SKYE United States
- BDTX United States
- Employees
- SKYE N/A
- BDTX N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SKYE Health Care
- BDTX Health Care
- Exchange
- SKYE Nasdaq
- BDTX Nasdaq
- Market Cap
- SKYE 73.4M
- BDTX 132.5M
- IPO Year
- SKYE N/A
- BDTX 2020
- Fundamental
- Price
- SKYE $4.32
- BDTX $2.41
- Analyst Decision
- SKYE Buy
- BDTX Strong Buy
- Analyst Count
- SKYE 6
- BDTX 5
- Target Price
- SKYE $16.60
- BDTX $15.60
- AVG Volume (30 Days)
- SKYE 1.9M
- BDTX 1.4M
- Earning Date
- SKYE 08-08-2025
- BDTX 08-05-2025
- Dividend Yield
- SKYE N/A
- BDTX N/A
- EPS Growth
- SKYE N/A
- BDTX N/A
- EPS
- SKYE N/A
- BDTX 0.09
- Revenue
- SKYE N/A
- BDTX $70,000,000.00
- Revenue This Year
- SKYE N/A
- BDTX N/A
- Revenue Next Year
- SKYE N/A
- BDTX N/A
- P/E Ratio
- SKYE N/A
- BDTX $27.30
- Revenue Growth
- SKYE N/A
- BDTX N/A
- 52 Week Low
- SKYE $1.14
- BDTX $1.20
- 52 Week High
- SKYE $8.26
- BDTX $6.75
- Technical
- Relative Strength Index (RSI)
- SKYE 81.18
- BDTX 57.88
- Support Level
- SKYE $2.12
- BDTX $2.15
- Resistance Level
- SKYE $2.22
- BDTX $2.71
- Average True Range (ATR)
- SKYE 0.35
- BDTX 0.17
- MACD
- SKYE 0.20
- BDTX -0.01
- Stochastic Oscillator
- SKYE 84.03
- BDTX 55.36
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.